Shire plc enters into agreement for development and commercialization of AB Biosciences’ PRIM program for potential treatment of autoimmune diseases and other immune-mediated disorders (146.93)
- Cos announced that they have entered into an agreement granting Shire an exclusive worldwide license to develop and commercialize AB Biosciences' pan receptor interacting molecule program, which uses AB Biosciences' proprietary oligomeric Fc technology platform. PRIM, a recombinant immunoglobulin product candidate, has shown encouraging preclinical data, including enhanced biological activity relative to currently approved intravenous immunoglobulin (IVIg) therapies, in preclinical models of autoimmune and inflammatory diseases.